Trinity Biotech Advances CGM+ Platform with Key Technical Breakthroughs
Event summary
- Trinity Biotech reports significant improvements in glucose measurement accuracy for its CGM+ platform, reducing Mean Absolute Relative Difference (MARD) across multi-day wear.
- Company anticipates initiating a pivotal clinical trial for CGM+ in 2026, targeting regulatory submissions immediately thereafter.
- Updated electronics architecture supports multimodal sensing and AI-native analytics for personalized metabolic health insights.
- CGM+ modular design aims to reduce costs and improve sustainability compared to current market-leading CGMs.
- Trinity Biotech positions CGM+ to participate in the fast-growing $15 billion CGM market and adjacent sectors.
The big picture
Trinity Biotech's advancements in its CGM+ platform come at a time when the continuous glucose monitoring market is projected to grow significantly, reaching $31.4 billion by 2031. The integration of AI-native analytics and multimodal sensing positions CGM+ to capture a share of the expanding AI in healthcare market, forecasted to reach $250 billion by 2031. The company's focus on reducing costs and improving sustainability aligns with broader industry trends toward more affordable and accessible health technologies.
What we're watching
- Regulatory Pathway
- The pace at which Trinity Biotech can navigate regulatory approvals for CGM+ will determine its market entry timeline.
- Market Adoption
- Whether CGM+ can differentiate itself in the competitive $15 billion CGM market through its multimodal sensing and AI capabilities.
- Cost Efficiency
- How the modular design of CGM+ will impact production costs and sustainability, potentially lowering barriers to adoption.
Related topics